Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)
PRESC1SE-MI
PRospective Evaluation of the European Society of Cardiology 0/1-hour Algorithm's Safety and Efficacy for Triage of Patients With Suspected Myocardial Infarction (PRESC1SE-MI)
2 other identifiers
interventional
64,374
10 countries
19
Brief Summary
The PRESC1SE-MI study compares two algorithms for triage of patients presenting with chest pain and symptoms of heart attack (myocardial infarction) to the emergency department. Both algorithms are recommended by the European Society of Cardiology: the 0/3-hour algorithm and the 0/1-hour algorithm. Currently, most emergency departments worldwide use the 0/3-hour troponin algorithm. Cardiac troponin (cTn) is a heart-specific biomarker which indicates damage of the heart muscle and which increases after a heart attack. In the 0/3-hour algorithm, the amount of troponin in the bloodstream is measured with a high-sensitivity assay at admission and 3 hours thereafter. Likewise, the 0/1-hour algorithm means that the blood sample in which the troponin is measured is collected at admission and 1 hour later. Since recent clinical studies suggest that the 0/1-hour algorithm is superior to the 0/3-hour algorithm, many hospitals consider switching to the 0/1-hour algorithm. The aim of this study is to assess how feasible the time-saving 0/1-hour algorithm would be in reality and whether it provides the same accuracy and safety in the diagnosis of myocardial infarction as the current practice the 0/3-hour algorithm.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2020
Longer than P75 for not_applicable
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2020
CompletedFirst Submitted
Initial submission to the registry
November 14, 2022
CompletedFirst Posted
Study publicly available on registry
December 14, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2028
September 17, 2026
September 1, 2026
7.1 years
November 14, 2022
September 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Composite of all-cause mortality or new AMI (type 1) occurring within 30 days of index presentation
Mortality rate and number of newly diagnosed AMI (type 1) in all enrolled patients
30 days
Time from ED presentation to ED discharge or transfer
Length of stay in the ED measured in hours
30 days
Secondary Outcomes (13)
Proportion of patients managed as outpatients
24 hours
Readmission for suspected AMI within 30 days after index presentation
30 days
All-cause mortality at 30 days in all patients
30 days
All-cause mortality at 365 days in all patients
365 days
New AMI (type1) at 30 days in all patients
30 days
- +8 more secondary outcomes
Study Arms (2)
0/1-hour algorithm
EXPERIMENTALHigh-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
0/3-hour algorithm
ACTIVE COMPARATORHigh-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
Interventions
High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
Eligibility Criteria
You may qualify if:
- Patients aged 18 and above
- Presentation with acute non-traumatic acute chest pain to the emergency department
- Suspicion of acute myocardial infarction
You may not qualify if:
- Terminal kidney failure requiring dialysis
- Cardiac arrest
- Cardiogenic shock
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Baylor St. Luke's Medical Center
Houston, Texas, 77030, United States
St Andrew's War Memorial Hospital Brisbane
Brisbane, Australia
Vienna General Hospital (AKH Wien)
Vienna, Austria
University Central Hospital Helsinki
Helsinki, Finland
Attikon General Hospital Athens
Athens, Greece
Careggi University Hospital Florence
Florence, Italy
Azienda Ospedaliera San Giovanni Addolorata
Roma, Italy
Hospital Città della Salute e della Scienza di Torino
Torino, Italy
Emergency Institute for Cardiovascular Diseases C.C. Iliescu
Bucharest, Romania
Konkuk University Medical Center
Seoul, South Korea
Hospital Clinic Barcelona
Barcelona, Spain
University Hospital October 12 Madrid
Madrid, Spain
University Hospital Ramon y Cajal
Madrid, Spain
Hospital Clínico Universitario Valencia
Valencia, Spain
Kantonsspital Aarau
Aarau, Switzerland
St. Claraspital
Basel, Switzerland
Kantonsspital Luzern
Lucerne, Switzerland
University Hospital Zurich
Zurich, Switzerland
Royal London Hospital
London, United Kingdom
Royal Cornwall Hospitals Treliske
Truro, United Kingdom
Related Publications (2)
Boeddinghaus J, Bima P, Crisanti L, Keller DI, Slankamenac K, Christ M, Schuetz P, Wiencierz A, Strebel I, Reinhardt J, Vyshnevska I, Tsao TY, Ruggieri MP, Steuer S, Miro O, Harjola VP, Morello F, Nazerian P, Roth D, Zamorano JL, Gannon DE, Pott J, Bloom B, Zubaid R, Bicette R, Cuculici A, Bueno H, Sanchis J, Mahfoud F, Abubakr MOA, Yang HS, Mueller C; PRESC1SE-MI investigators. Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial. Lancet. 2026 Aug 29:S0140-6736(26)01654-5. doi: 10.1016/S0140-6736(26)01654-5. Online ahead of print.
PMID: 42667934DERIVEDBoeddinghaus J, Bima P, Crisanti L, Keller DI, Slankamenac K, Christ M, Schuetz P, Wiencierz A, Strebel I, Reinhardt J, Vyshnevska I, Tsao TY, Mahfoud F, Ruggieri MP, Steuer S, Miro O, Harjola VP, Morello F, Nazerian P, Roth D, Zamorano JL, Gannon DE, Pott J, Abubakr MO, Yang HS, Young J, Bicette R, Cuculici A, Bueno H, Sanchis J, Mueller C; PRESC1SE-MI investigators. PRospective evaluation of the European Society of Cardiology 0/1h-algorithm;s safety and efficacy for triage of patients with suspected myocardial infarction (PRESC1SE-MI): Rationale and design of a prospective international multicenter stepped-wedge cluster randomized controlled trial. Am Heart J. 2026 Feb;292:107299. doi: 10.1016/j.ahj.2025.107299. Epub 2025 Oct 31.
PMID: 41177204DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christian Müller, MD Prof.
University Hospital, Basel, Switzerland
- PRINCIPAL INVESTIGATOR
Jasper Boeddinghaus, MD
University Hospital, Basel, Switzerland
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 14, 2022
First Posted
December 14, 2022
Study Start
December 1, 2020
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
May 31, 2028
Last Updated
September 17, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- Beginning 6 months after publication and ending 1 year after publication.
- Access Criteria
- Requests to access de-identified individual participant data that underlie the results reported in this Article for academic, non-profit purposes can be sent to christian.mueller@usb.ch. Data availability will begin 6 months after publication. The anticipated timeframe for response is around 4 weeks. A data dictionary, the study protocol, and the statistical analysis plan can be made available. All requests will be reviewed by the corresponding author, the ethics committees, and University Hospital Basel to evaluate the merit of the research proposed, the availability of the data, the intended use of the data, and the presence of conflicts of interest. A signed data access agreement with the sponsor is required before data sharing.
De-identified individual participant data underlying the results reported in the article will be available for academic, non-profit purposes. A data dictionary, the study protocol, and the statistical analysis plan may also be made available.